Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
about
Bisphosphonates for prevention of bone loss in women with early breast cancerBreast cancer in the personal genomics eraTamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionTamoxifen: catalyst for the change to targeted therapyHerbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-AnalysisAdjuvant systemic therapy in older women with breast cancerClinical utility of letrozole in the treatment of breast cancer: a Chinese perspectivePrevention and treatment of bone fragility in cancer patientEarly-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineAdjuvant treatment for older women with invasive breast cancerClinical utilities of aromatase inhibitors in breast cancerCardiac risk in the treatment of breast cancer: assessment and management.Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysisThe National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trialCancer drug related cardiotoxicity during breast cancer treatment.The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Status of adjuvant endocrine therapy for breast cancer.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Managing aromatase inhibitors in breast cancer survivors: not just for oncologistsThe Long and Short of Tamoxifen Therapy: A Review of the ATLAS TrialThe HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.A joint test for progression and survival with interval-censored data from a cancer clinical trialFactor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerBreast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.Adjuvant Endocrine Therapy in Premenopausal PatientsAdjuvant Endocrine Therapy in Early Postmenopausal Breast CancerA prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
P2860
Q24240547-C05F7D4D-3FC7-460F-BFB1-2F3F606E71BDQ24602679-D9F638F4-2736-475E-9620-41E1A81B520FQ24605762-04FA7574-FB63-4EF8-9BEC-F3B1C8FEA668Q24652988-57522370-BA36-4691-946A-84ACA3FF2D46Q26740203-6B2D3136-A4C6-4699-9B6B-828BB3CC95C5Q26741523-23A50803-55AD-48F2-961D-2FECB9F5BB90Q26752834-E33E1E82-FD43-4342-B0B7-7514AD0A28DEQ26775765-2CBE52A3-1ACF-4A04-9FEA-CA16E0D3DC87Q26782584-D9D1CAEF-1575-4A3B-BB29-EF51B38E10F6Q27002430-D9ED217A-C66B-4502-8462-D45F2879BE6FQ28066744-F67A3B02-2301-4268-95DD-62429C538A29Q28081168-52842F22-4B33-42CB-97E7-0411FB3414B1Q28081385-1012E948-8931-448D-8675-D0443DCB8332Q28087204-E95B4FA3-A708-4229-A0E2-4120B3EFF61AQ28217652-DA8FC884-C829-4BB3-B898-C70F4F912031Q30251498-E4C10072-F3E6-4CB1-BDBF-9496F1BFD179Q33477635-68460854-682F-48A3-9904-E86FEF65FEE4Q33531646-C653CFC8-50EE-4447-A1BD-2AA4C7FD693AQ33618145-968E3D53-49DA-408A-A4AA-B3A06F6343B2Q33684843-B7393080-9A28-4A0D-BECE-AD93D6BCD4D6Q33698446-ABB1470B-BD7B-4385-9350-293B7E93C7C9Q33739138-1911358E-E4F6-4028-BCE8-4D4F721F56B3Q33787731-86E52686-27F2-4A20-98F2-919588824933Q33794923-860484BC-825F-4C60-A73B-E73AB1F543E7Q33795923-24CC0F69-B997-4318-8C84-312948BB0F83Q33827057-0818F45A-E3A0-4267-8B8C-9D1B3AED8A04Q33884184-47B266CD-425C-47BD-BA24-1EF983E02D97Q33886176-73FC8B27-EE6C-44B7-A7C4-4314B557EAA4Q33934350-F9AABA3D-66AC-4259-B7D2-2C8B6602C50AQ33959131-357F3B3E-7053-448D-826D-E609B91715AAQ33965106-A51FB657-8980-48D7-804B-469C5BB3F6FDQ34023239-B63D3E41-794E-403C-B68A-7BB6CE371970Q34045510-7EE77478-8683-479E-8CCA-55F602414D19Q34059713-B3367274-2C4F-4E87-ADBC-29D90371E41BQ34096277-3F122684-64CA-45C0-B5DE-5121CCA6F732Q34096283-745AEF7B-6912-40E7-984F-3D0222AEB2B9Q34116012-ED02AC5E-9F36-434D-A934-CC655B3A1958Q34140072-ECD24894-E033-4C54-94D7-52CD49035412Q34143532-3FE73988-3784-4DB4-BB63-8F7723F104B6Q34148380-A52EF838-3CA2-46B9-BFCB-E572BDD40FA3
P2860
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@en
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@nl
type
label
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@en
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@nl
prefLabel
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@en
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@nl
P2093
P356
P1476
Randomized trial of letrozole ...... findings from NCIC CTG MA.17.
@en
P2093
David A Cameron
Dongsheng Tu
Edith A Perez
Hyman B Muss
James N Ingle
Jeffrey S Abrams
Joseph L Pater
Kathleen I Pritchard
Lois E Shepherd
Martine J Piccart
P304
P356
10.1093/JNCI/DJI250
P407
P50
P577
2005-09-01T00:00:00Z